ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1927

Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation

Tomoya Watanabe1, Tetsuya Nishimoto2, Takahisa Takihara3, Logan Mlakar4, Yunyun Su5 and Carol A. Feghali-Bostwick6, 1Rheumatology, Medical University of South Carolina, Charleston, SC, 2Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 3Division of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Japan, 4Medical University of South Carolina, Charleston, SC, 5Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, charleston, SC, 6Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Fibroblasts, fibrosis and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Fibrotic disorders such as systemic sclerosis (SSc) result in end-stage organ failure and loss of function, consequently causing high morbidity and mortality. We recently demonstrated that the C-terminal domain of endostatin, known as E4, prevented and reversed both dermal and pulmonary fibrosis. In this study, we investigated the mechanism by which E4 exerts anti-fibrotic effects using pre-clinical models of SSc.

Methods:

To assess the effects of E4, lung fibroblasts were treated with TGF-β with vehicle or E4. The expression levels and activity of matrix metalloproteases (MMP)-1 and MMP-3 were evaluated by using real-time PCR, immunoblotting (IB), and collagen and casein zymography, respectively. Furthermore, the mRNA and protein levels of the pro-fibrotic proteins, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein (IGFBP)-3, were measured using real-time PCR and IB, respectively. In vivo, bleomycin with vehicle or E4 was administered intratracheally to 6 to 8-week-old C57BL/6J male mice to induce lung fibrosis. Lung and bronchoalveolar lavage fluid (BALF) were collected 7 days post-treatment, and the levels and activity of hepatocyte growth factor (HGF) were measured using real-time PCR and immunoblotting.

Results:

The mRNA levels of MMP-1 and MMP-3 were increased by E4. Similarly, secreted MMP-1 and MMP-3 protein levels were upregulated in culture supernatants. Furthermore, MMP-1 and MMP-3 activity was increased as assessed by zymography. TGF-β increased the expression levels of CTGF and IGFBP-3 in primary human fibroblasts, and E4 abrogated these effects. In vivo, bleomycin reduced HGF levels in BALF and lung tissues. E4 peptide partially blocked these effects.

Conclusion:

Our results demonstrate that E4 increased MMP-1 and MMP-3 levels and activity. The ability of E4 to reverse fibrosis can thus be explained, in part, by its increase of MMP, thus promoting extracellular matrix (ECM) degradation. In addition, E4 reduced levels of the pro-fibrotic mediators CTGF and IGFBP-3 while increasing levels of the anti-fibrotic and anti-inflammatory factor HGF. Our findings suggest that the anti-fibrotic effects of E4 peptide are multi-pronged and include decreasing levels of essential pro-fibrotic mediators, increasing levels of an anti-fibrotic mediator, and promoting ECM degradation.


Disclosure: T. Watanabe, None; T. Nishimoto, None; T. Takihara, None; L. Mlakar, None; Y. Su, None; C. A. Feghali-Bostwick, None.

To cite this abstract in AMA style:

Watanabe T, Nishimoto T, Takihara T, Mlakar L, Su Y, Feghali-Bostwick CA. Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-fibrotic-mechanisms-of-endostatin-derived-peptide-are-the-result-of-reduction-in-pro-fibrotic-mediators-and-promotion-of-extracellular-matrix-degradation/. Accessed September 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-fibrotic-mechanisms-of-endostatin-derived-peptide-are-the-result-of-reduction-in-pro-fibrotic-mediators-and-promotion-of-extracellular-matrix-degradation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology